Noerager B D, Inuzuka T, Kira J, Blalock J E, Whitaker J N, Galin F S
Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
J Neuroimmunol. 2001 Feb 1;113(1):163-9. doi: 10.1016/s0165-5728(00)00425-2.
In a previously described case of Waldenstrom's Macroglobulinemia, complicated by polyneuropathy, the IgM/lambda monoclonal antibody (mAb) was highly reactive with myelin basic protein (MBP). Given our demonstration that V lambda x, a recently described murine lambda variable region gene product, can itself bind MBP as well as confer MBP reactivity to an Ab, the possibility of a shared idiotypy between murine V lambda x and this human IgM/lambda anti-MBP was investigated. We characterized the epitope specificity of the macroglobulinemia patient's MBP-reactive IgM/lambda using indirect ELISA procedures with MBP, a citrullinated isomer of MBP termed C8, or peptide fragments of MBP as the coating antigens and monospecific Ab to V lambda x as the secondary Ab. The patient's MBP-reactive IgM/lambda was recognized by Ab specific for V lambda x and, like murine mAb containing V lambda x bound human MBP but not MBP-C8 nor other common autoantigens such as DNA, thyroglobulin, or actin. The anti-MBP reactivity was selective for MBP peptide 90-170 and preferentially recognized MBP peptide 84-96. Thus, the patient's macroglobulin and perhaps certain other human Ab with a 'V lambda x idiotype' bind to MBP peptide residues 84-96, an immunodominant peptide in multiple sclerosis patients. Such binding may be involved in the pathogenesis of neural damage in patients with neuroimmunologic disorders related to plasma cell dyscrasias or autoimmunity.
在先前描述的一例伴有多发性神经病的华氏巨球蛋白血症病例中,IgM/λ单克隆抗体(mAb)与髓鞘碱性蛋白(MBP)高度反应。鉴于我们已证明Vλx(一种最近描述的鼠λ可变区基因产物)自身可结合MBP并赋予抗体MBP反应性,于是研究了鼠Vλx与这种人类IgM/λ抗MBP之间存在共同独特型的可能性。我们采用间接ELISA方法,以MBP、一种名为C8的MBP瓜氨酸化异构体或MBP的肽片段作为包被抗原,以针对Vλx的单特异性抗体作为二抗,来表征巨球蛋白血症患者MBP反应性IgM/λ的表位特异性。该患者的MBP反应性IgM/λ被针对Vλx的特异性抗体识别,并且与含有Vλx的鼠单克隆抗体一样,能结合人MBP,但不能结合MBP-C8或其他常见自身抗原,如DNA、甲状腺球蛋白或肌动蛋白。抗MBP反应性对MBP肽90 - 170具有选择性,且优先识别MBP肽84 - 96。因此,该患者的巨球蛋白以及可能某些其他具有“Vλx独特型”的人类抗体与MBP肽残基84 - 96结合,这是多发性硬化症患者中的一个免疫显性肽段。这种结合可能参与了与浆细胞发育异常或自身免疫相关的神经免疫疾病患者神经损伤的发病机制。